{
  "links": "https://www.ycombinator.com/companies/gilgamesh-pharmaceuticals",
  "name": "Gilgamesh Pharmaceuticals",
  "headline": "Gilgamesh Pharmaceuticals, a Clinical stage biotechnology companyâ¦",
  "batch": "S20",
  "description": "Gilgamesh is a pioneering, clinical stage mental health science-focused biotechnology company. We have a disciplined focus on developing innovative new chemical entities (NCEs) leveraging a unique combination of medicinal chemistry, intellectual property strategy, neuroscience & neurobiology, and drug development expertise. We are an experienced team, with proven success in biotech exits and inventions.",
  "activity_status": "Active",
  "website": "https://www.gilgameshpharmaceutical.com",
  "founded_date": 2019.0,
  "team_size": 15.0,
  "location": "New York",
  "group_partner": "Jared Friedman",
  "group_partner_yc": "https://www.ycombinator.com/people/jared-friedman",
  "company_linkedin": null,
  "company_twitter": null,
  "tags": "industry:therapeutics; industry:psychedelics; industry:mental-health; location:new-york",
  "founders": [
    {
      "name": "JONATHAN SPORN, Founder",
      "description": "Duke University BS, MD from University of Miami, former Chief of Psychiatry in Boston Area.\nAcademic work at Mass General Hospital and NIH (intramural), researcher at JNJ in psychiatry and neurology, and then at Pfizer Inc in NYC (Clinical Disease Area Expert in Neuroscience Area), Founder of start up, Perception Neuroscience (exited) and was CSO, and now Founder of Gilgamesh. Live in NYC and mountains of NC. Assistant Professor of Psychiatry and Exp Therapeutics at Columbia University",
      "linkedin": "https://www.linkedin.com/in/jonathan-sporn-4ba7802/?lipi=urn%3Ali%3Apage%3Ad_flagship3_feed%3BsZ0EMprfTbaqKu56p%2Bd6%2FA%3D%3D"
    },
    {
      "name": "Andrew Kruegel, Founder",
      "description": "I am a medicinal chemist, pharmacologist, and entrepreneur with extensive experience in the design and preclinical development of psychoactive drugs for the future treatment of psychiatric illnesses. In the context of my entrepreneurial endeavors I have also built significant expertise in business, fundraising, operations, and intellectual property strategy.",
      "linkedin": "https://www.linkedin.com/in/andrew-kruegel-39091a9b/"
    },
    {
      "name": "Dalibor Sames, Founder",
      "description": "Professor of Chemistry at Columbia University with expertise in synthetic chemistry, medicinal chemistry, molecular design, synaptic imaging, neuropharmacology, and experimental therapeutics. Led new conceptual advances in chemical synthesis (C-H bond functionalization), developed fluorescent false neurotransmitters (FFNs), elucidated the mechanism of action of antidepressant tianeptine, expertise in iboga alkaloid and mitragynines chemistry and pharmacology.",
      "linkedin": "https://www.linkedin.com/in/dalibor-sames-04031815b"
    }
  ],
  "status": true,
  "markdown": "raw_markdown='[](https://www.gilgameshpharmaceutical.com/</>)[About/NEWS](https://www.gilgameshpharmaceutical.com/</about>)[team](https://www.gilgameshpharmaceutical.com/</team>)[Pipeline](https://www.gilgameshpharmaceutical.com/</pipeline>)[Contact Us](https://www.gilgameshpharmaceutical.com/</contact-us>)\\n#### An Epic Leap For Mental Health\\nGilgamesh Pharmaceuticals is a clinical stage neuroscience biotech developing innovative, best-in-class new chemical entities (NCEs) that target the root causes of psychiatric disorders, moving away from symptom management towards rapid-acting and long-lasting therapies \\n[About the Company](https://www.gilgameshpharmaceutical.com/</about>)[Our Pipeline](https://www.gilgameshpharmaceutical.com/</pipeline>)\\nOur programs\\n#### Deep expertise in medicinal chemistry combined with our AI-powered discovery and translational platform accelerates the creation of our novel precision psychiatric therapies.\\n![](https://cdn.prod.website-files.com/60f9d9fb2e7687162e692830/611c9971fe616f175bcee0b1_gilgamesh-icon.svg)\\n**NMDAR Antagonist**\\n  * Orally bioavailable\\n  * Rapid-acting\\n  * Fewer dissociative effects\\n  * Depression and other indications\\n  * New Chemical Entity \\n\\n\\n![](https://cdn.prod.website-files.com/60f9d9fb2e7687162e692830/611c9971fe616f175bcee0b1_gilgamesh-icon.svg)\\n**5-HT2AR Agonists**\\n  * Rapid acting anti-depressants\\n  * Optimized duration of effect\\n  * Improved cardiac safety profile\\n  * Depression and other indications\\n  * New Chemical Entities \\n\\n\\n![](https://cdn.prod.website-files.com/60f9d9fb2e7687162e692830/611c9971fe616f175bcee0b1_gilgamesh-icon.svg)\\n**Non-Hallucinogenic Neuroplastogens**\\n  * Rapid acting \\n  * Orally bioavailable\\n  * Non-Hallucinogenic\\n  * Depression and other indications\\n  * New Chemical Entities \\n\\n\\n![](https://cdn.prod.website-files.com/60f9d9fb2e7687162e692830/611c9971fe616f175bcee0b1_gilgamesh-icon.svg)\\n**Safer Ibogaine Analogs**\\n  * Rapid and sustained efficacy\\n  * Improved cardiac safety profile\\n  * Opioid use disorder and other indications\\n  * New Chemical Entity\\n\\n\\n[Our Pipeline](https://www.gilgameshpharmaceutical.com/</pipeline>)\\nOur Partners\\nWe collaborate with pharma partners and research institutions at the forefront of biotech innovation.\\n![Columbia University Logo](https://cdn.prod.website-files.com/60f9d9fb2e7687162e692830/66420da60637e6502c4fc2f3_abbvie%202.svg)![Columbia University Logo](https://cdn.prod.website-files.com/60f9d9fb2e7687162e692830/66420e36f89e3bdf039306ca_NIDA.png)![NIDA Logo](https://cdn.prod.website-files.com/60f9d9fb2e7687162e692830/66420e912b2fa865115d8919_Columbia%20Un..png)\\n[our team](https://www.gilgameshpharmaceutical.com/</team>)\\nLearn more about partnerships, investment, and career opportunities\\n[Contact Us](https://www.gilgameshpharmaceutical.com/</contact-us>)\\n![](https://cdn.prod.website-files.com/60f9d9fb2e7687162e692830/6115e0d887809dc25b898d43_Union.svg)\\n[Home](https://www.gilgameshpharmaceutical.com/</>)\\n[About](https://www.gilgameshpharmaceutical.com/</about>)\\n[Team](https://www.gilgameshpharmaceutical.com/</team>)\\n[Pipeline](https://www.gilgameshpharmaceutical.com/</pipeline>)\\n[Contact Us](https://www.gilgameshpharmaceutical.com/</contact-us>)\\n[Twitter](https://www.gilgameshpharmaceutical.com/<https:/twitter.com/gilgameshrx>)\\n[LinkedIn](https://www.gilgameshpharmaceutical.com/<https:/www.linkedin.com/company/gilgamesh-pharmaceuticals/>)\\nGilgamesh Pharmaceuticals\\n113 University Place, Suite 1019, NY, NY 10003[info@gilgameshpharmaceutical.com](https://www.gilgameshpharmaceutical.com/<#>)\\n[Privacy Policy,](https://www.gilgameshpharmaceutical.com/<https:/mcusercontent.com/6c3f21fb747d330b7d588cc87/files/05ad878c-a5ab-7b1c-33ee-517c3ea8737b/Gilgamesh_Privacy_Policy_3.7.24.pdf>)[ FCOI](https://www.gilgameshpharmaceutical.com/<https:/mcusercontent.com/6c3f21fb747d330b7d588cc87/files/ff02cf7c-226d-e23a-b373-2c350f9c69e2/GILGAMESH_POLICY_ON_FINANCIAL_CONFLICTS_OF_INTEREST_IN_PUBLIC_HEALTH_SERVICE_FUNDED_RESEARCH_002_.pdf>)\\n' markdown_with_citations='[](https://www.gilgameshpharmaceutical.com/</>)About/NEWS⟨1⟩team⟨2⟩Pipeline⟨3⟩Contact Us⟨4⟩\\n#### An Epic Leap For Mental Health\\nGilgamesh Pharmaceuticals is a clinical stage neuroscience biotech developing innovative, best-in-class new chemical entities (NCEs) that target the root causes of psychiatric disorders, moving away from symptom management towards rapid-acting and long-lasting therapies \\nAbout the Company⟨1⟩Our Pipeline⟨3⟩\\nOur programs\\n#### Deep expertise in medicinal chemistry combined with our AI-powered discovery and translational platform accelerates the creation of our novel precision psychiatric therapies.\\n![](https://cdn.prod.website-files.com/60f9d9fb2e7687162e692830/611c9971fe616f175bcee0b1_gilgamesh-icon.svg)\\n**NMDAR Antagonist**\\n  * Orally bioavailable\\n  * Rapid-acting\\n  * Fewer dissociative effects\\n  * Depression and other indications\\n  * New Chemical Entity \\n\\n\\n![](https://cdn.prod.website-files.com/60f9d9fb2e7687162e692830/611c9971fe616f175bcee0b1_gilgamesh-icon.svg)\\n**5-HT2AR Agonists**\\n  * Rapid acting anti-depressants\\n  * Optimized duration of effect\\n  * Improved cardiac safety profile\\n  * Depression and other indications\\n  * New Chemical Entities \\n\\n\\n![](https://cdn.prod.website-files.com/60f9d9fb2e7687162e692830/611c9971fe616f175bcee0b1_gilgamesh-icon.svg)\\n**Non-Hallucinogenic Neuroplastogens**\\n  * Rapid acting \\n  * Orally bioavailable\\n  * Non-Hallucinogenic\\n  * Depression and other indications\\n  * New Chemical Entities \\n\\n\\n![](https://cdn.prod.website-files.com/60f9d9fb2e7687162e692830/611c9971fe616f175bcee0b1_gilgamesh-icon.svg)\\n**Safer Ibogaine Analogs**\\n  * Rapid and sustained efficacy\\n  * Improved cardiac safety profile\\n  * Opioid use disorder and other indications\\n  * New Chemical Entity\\n\\n\\nOur Pipeline⟨3⟩\\nOur Partners\\nWe collaborate with pharma partners and research institutions at the forefront of biotech innovation.\\n![Columbia University Logo⟨5⟩]![Columbia University Logo⟨6⟩]![NIDA Logo⟨7⟩]\\nour team⟨2⟩\\nLearn more about partnerships, investment, and career opportunities\\nContact Us⟨4⟩\\n![](https://cdn.prod.website-files.com/60f9d9fb2e7687162e692830/6115e0d887809dc25b898d43_Union.svg)\\nHome⟨8⟩\\nAbout⟨1⟩\\nTeam⟨2⟩\\nPipeline⟨3⟩\\nContact Us⟨4⟩\\nTwitter⟨9⟩\\nLinkedIn⟨10⟩\\nGilgamesh Pharmaceuticals\\n113 University Place, Suite 1019, NY, NY 10003info@gilgameshpharmaceutical.com⟨11⟩\\nPrivacy Policy,⟨12⟩ FCOI⟨13⟩\\n' references_markdown='\\n\\n## References\\n\\n⟨1⟩ https://www.gilgameshpharmaceutical.com/</about>: About/NEWS\\n⟨2⟩ https://www.gilgameshpharmaceutical.com/</team>: team\\n⟨3⟩ https://www.gilgameshpharmaceutical.com/</pipeline>: Pipeline\\n⟨4⟩ https://www.gilgameshpharmaceutical.com/</contact-us>: Contact Us\\n⟨5⟩ https://cdn.prod.website-files.com/60f9d9fb2e7687162e692830/66420da60637e6502c4fc2f3_abbvie%202.svg: Columbia University Logo\\n⟨6⟩ https://cdn.prod.website-files.com/60f9d9fb2e7687162e692830/66420e36f89e3bdf039306ca_NIDA.png: Columbia University Logo\\n⟨7⟩ https://cdn.prod.website-files.com/60f9d9fb2e7687162e692830/66420e912b2fa865115d8919_Columbia%20Un..png: NIDA Logo\\n⟨8⟩ https://www.gilgameshpharmaceutical.com/</>: Home\\n⟨9⟩ https://www.gilgameshpharmaceutical.com/<https:/twitter.com/gilgameshrx>: Twitter\\n⟨10⟩ https://www.gilgameshpharmaceutical.com/<https:/www.linkedin.com/company/gilgamesh-pharmaceuticals/>: LinkedIn\\n⟨11⟩ https://www.gilgameshpharmaceutical.com/<#>: info@gilgameshpharmaceutical.com\\n⟨12⟩ https://www.gilgameshpharmaceutical.com/<https:/mcusercontent.com/6c3f21fb747d330b7d588cc87/files/05ad878c-a5ab-7b1c-33ee-517c3ea8737b/Gilgamesh_Privacy_Policy_3.7.24.pdf>: Privacy Policy,\\n⟨13⟩ https://www.gilgameshpharmaceutical.com/<https:/mcusercontent.com/6c3f21fb747d330b7d588cc87/files/ff02cf7c-226d-e23a-b373-2c350f9c69e2/GILGAMESH_POLICY_ON_FINANCIAL_CONFLICTS_OF_INTEREST_IN_PUBLIC_HEALTH_SERVICE_FUNDED_RESEARCH_002_.pdf>:  FCOI\\n' fit_markdown='' fit_html=''",
  "generated_description": "**Company Overview: Gilgamesh Pharmaceuticals**\n\nFounded in 2019 and part of Y Combinator's Batch S20, Gilgamesh Pharmaceuticals is a New York-based clinical-stage biotechnology company focused on revolutionizing mental health treatment. The firm has a lean yet proficient team of 15 employees and is helmed by experienced biotech expert Jared Friedman as their Group Partner.\n\n**Mission and Vision**\n\nGilgamesh Pharmaceuticals is on a mission to develop innovative new chemical entities (NCEs) aimed at addressing the root causes of psychiatric disorders. By moving beyond traditional symptom management, they strive to create rapid-acting, long-lasting therapies that can significantly improve the lives of those facing mental health challenges.\n\n**Core Expertise**\n\nThe company combines deep expertise in medicinal chemistry with advanced AI-powered discovery methods—an intriguing blend that accelerates the development of precision psychiatric therapies. Their focus areas include various novel treatments for depression and other psychiatric conditions, marked by an emphasis on safety and efficacy.\n\n**Innovative Pipeline**\n\nGilgamesh is pioneering several promising treatments, including:\n\n1. **NMDAR Antagonists**: These are designed to be orally bioavailable and rapid-acting, minimizing dissociative effects.\n  \n2. **5-HT2AR Agonists**: Optimized to act quickly as antidepressants while maintaining a safer cardiac profile.\n  \n3. **Non-Hallucinogenic Neuroplastogens**: Offering rapid action without hallucinogenic effects, these entities aim to treat depression and similar disorders.\n  \n4. **Safer Ibogaine Analogs**: Tailored for opioid use disorder, these new chemical entities combine sustained efficacy with improved safety records.\n\n**Collaborations and Partnerships**\n\nGilgamesh Pharmaceuticals collaborates with leaders in pharmaceutical and academic research, including respected institutions like Columbia University and the National Institute on Drug Abuse (NIDA). Such partnerships are pivotal for driving innovation and expanding their therapeutic impact.\n\n**Contact and Further Information**\n\nTo explore their journey in mental health science further, Gilgamesh Pharmaceuticals invites interested parties to visit their website at [gilgameshpharmaceutical.com](https://www.gilgameshpharmaceutical.com) for more insights into their pipeline, team, and contact options.\n\nIn summary, Gilgamesh Pharmaceuticals stands at the forefront of biotechnology innovation, with a clear commitment to enhancing mental health treatments. Their approach fuses rigorous scientific methodology with a compassionate goal—an endeavor that could reshape the landscape of psychiatric care."
}